Conatus Pharmaceuticals - Company & Market Research Reports

Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Its lead compound, emricasan, is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases. In December 2016, Conatus announced an exclusive option, collaboration and license agreement with Novartis for the global development and commercialization of emricasan. The company was founded in 2005 and is headquartered in San Diego, California.


Hepatitis Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Hepatitis Drug Development Pipeline Review, 2017

  • Report
  • 209 Pages
From
2018 hepatitis C Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 hepatitis C Drug Development- Pipeline Analysis Report

  • Report
  • 200 Pages
From
Liver Transplant Rejection - Pipeline Review, H1 2018 - Product Thumbnail Image

Liver Transplant Rejection - Pipeline Review, H1 2018

  • Report
  • 72 Pages
From
Liver Transplantation - Pipeline Review, H1 2016 - Product Thumbnail Image

Liver Transplantation - Pipeline Review, H1 2016

  • Report
  • 78 Pages
From
Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • 277 Pages
From
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies - Product Thumbnail Image

Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies

  • Report
  • 65 Pages
From
2018 Primary Sclerosing Cholangitis Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Primary Sclerosing Cholangitis Drug Development- Pipeline Analysis Report

  • Report
  • 48 Pages
From
Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022)  - Product Thumbnail Image

Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022)

  • Report
  • 210 Pages
From
Global Non-Alcoholic Steatohepatitis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025 - Product Thumbnail Image

Global Non-Alcoholic Steatohepatitis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • Report
From
NASH Drugs Market, 2015 - 2025 - Product Thumbnail Image

NASH Drugs Market, 2015 - 2025

  • Report
  • 188 Pages
From
Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products - Product Thumbnail Image

Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

  • Report
  • 76 Pages
From
Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) - Product Thumbnail Image

Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)

  • Report
  • 56 Pages
From
New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) - Product Thumbnail Image

New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)

  • Report
  • 56 Pages
From
Global Nonalcoholic Steatohepatitis Therapeutics and Diagnostics Market - Segmented by Pipeline Therapeutics, Diagnostic Techniques, Treatment Therapies, and Geography - Growth, Trends, and Forecast (2018 - 2023) - Product Thumbnail Image

Global Nonalcoholic Steatohepatitis Therapeutics and Diagnostics Market - Segmented by Pipeline Therapeutics, Diagnostic Techniques, Treatment Therapies, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • Report
  • 108 Pages
From
Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2027 - Product Thumbnail Image

Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2027

  • Drug Pipelines
  • 120 Pages
From
Polycystic Kidney Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Polycystic Kidney Disease - Pipeline Review, H1 2018

  • Report
  • 108 Pages
From
Liver Cirrhosis - Pipeline Review, H1 2018 - Product Thumbnail Image

Liver Cirrhosis - Pipeline Review, H1 2018

  • Report
  • 88 Pages
From
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017 - Product Thumbnail Image

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017

  • Report
  • 80 Pages
From
Primary Sclerosing Cholangitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Primary Sclerosing Cholangitis - Pipeline Review, H1 2018

  • Report
  • 106 Pages
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017

  • Report
  • 446 Pages
From
Loading Indicator
adroll